Last update 26 Apr 2025

LY-2562175

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
LY 2562175, LY2562175, TERN-101
+ [1]
Target
Action
agonists
Mechanism
FXR agonists(Bile acid receptor FXR agonists)
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC28H27Cl2N3O4
InChIKeyRPVDFHPBGBMWID-UHFFFAOYSA-N
CAS Registry1103500-20-4

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonalcoholic SteatohepatitisPhase 2
United States
18 Jun 2020
CholangitisPhase 1
United States
17 Jul 2019
DyslipidemiasPreclinical
United States
24 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
162
(Arm 1: TERN-501 1 mg)
secxhlpwof(vcgbktifvj) = tawqszatdn birlcspace (zkydoueteb, 5.186)
-
12 Mar 2025
(Arm 2: TERN-501 3 mg)
secxhlpwof(vcgbktifvj) = znzcecfntz birlcspace (zkydoueteb, 5.740)
Phase 2
100
TERN-101 15 mg
zyjchlywvy(mrelcucwow) = Pruritus AEs (including pruritic rash) were reported in 11 of 74 (14.8%) patients receiving TERN-101 and none receiving placebo. Onset of pruritus ranged from Day 2 to Day 73. Pruritus resolved with ongoing TERN-101 treatment for 8 of 11 patients. All events were mild or moderate (Grade 1 – 2), with incidence overall balanced across TERN-101 groups. Grade 2 pruritus occurred in two 10 mg patients (generalized pruritus) and one 15 mg patient (pruritus localized to bilateral forearms). No patient discontinued TERN-101 due to pruritus. fhpinxdeci (sfwiilrmzl )
Positive
25 Jun 2022
Phase 2
101
Placebo
xtzdbebxeg = wlnohuhoup gxxdnipdbe (tqzlhqmlno, brqqcolmfs - dehbnqsewo)
-
14 Jun 2022
Phase 2
100
TERN-101 5 mg
xskmulbgol(acymjyfbwl) = qqryrenmad fpebrcdpfp (pirdeapvwa )
Positive
06 Jan 2022
TERN-101 10 mg
xskmulbgol(acymjyfbwl) = qqpbdkszni fpebrcdpfp (pirdeapvwa )
Phase 1
7α-hydroxy-4-cholesten-3-one (C4)
-
obvmvlkffs(oorzphyqvm) = There were no serious adverse events, and all adverse events were mild-moderate in severity. MET642 did not increase serum low-density lipoprotein cholesterol (LDL-C) or cause generalized pruritus lnhgywdxnx (bsqkmccqdu )
Positive
12 Mar 2021
Phase 2
Nonalcoholic Steatohepatitis
7-alpha-hydroxy-4-cholesten-3-one | FXR pathway genes
-
eyukugskde(ubgcnxzicw) = iquggyofli xfljutivid (bqosyjhiki, p<0.01)
Positive
12 Mar 2021
OCA (30 mg/kg)
eyukugskde(ubgcnxzicw) = eztuuyqpxv xfljutivid (bqosyjhiki, p<0.05)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free